Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Rallybio's ebitda for the twelve months ending Sep 30, 2026 was -$24.21M. For fiscal 2025 it was -$32.97M. The highest annual figure on record is -$25.24M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.97M | – |
| FY2024 | Dec 31, 2024 | -$60.37M | – |
| FY2023 | Dec 31, 2023 | -$78.78M | – |
| FY2022 | Dec 31, 2022 | -$67.72M | – |
| FY2021 | Dec 31, 2021 | -$45.54M | – |
| FY2020 | Dec 31, 2020 | -$25.24M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.42M | – |
| Q2 FY2026 | Jun 30, 2026 | -$5.65M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$11.58M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.03M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$21.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.33M | – |
| Q2 FY2023 | Jun 30, 2023 | -$20.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.28M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.28M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.07M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.70M | – |
See a number that looks wrong?